New Pathfinder Study Analysis Demonstrates Efficient Diagnostic Resolution Following Multi-cancer Early Detection Testing

GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, recently presented results from a retrospective analysis of the interventional PATHFINDER study. The findings demonstrated that in the majority of cases (78%), the test’s cancer signal origin (CSO)-directed initial diagnostic evaluation led to a diagnostic resolution. The analysis was conducted on 39 PATHFINDER participants who received a cancer signal detected (CSD) result from both Galleri and an earlier version of the MCED test and had diagnostic evaluations.